{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:06:29Z","timestamp":1782000389559,"version":"3.54.5"},"reference-count":52,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["17K09039"],"award-info":[{"award-number":["17K09039"]}]},{"name":"JSPS KAKENHI","award":["20K08597"],"award-info":[{"award-number":["20K08597"]}]},{"name":"JSPS KAKENHI","award":["23K07707"],"award-info":[{"award-number":["23K07707"]}]},{"name":"Subsides for Ordinary Express of Private School, provided by The Promotion and Mutual Aid Corporation for Private School of Japan","award":["17K09039"],"award-info":[{"award-number":["17K09039"]}]},{"name":"Subsides for Ordinary Express of Private School, provided by The Promotion and Mutual Aid Corporation for Private School of Japan","award":["20K08597"],"award-info":[{"award-number":["20K08597"]}]},{"name":"Subsides for Ordinary Express of Private School, provided by The Promotion and Mutual Aid Corporation for Private School of Japan","award":["23K07707"],"award-info":[{"award-number":["23K07707"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>In 1968, Jean Berger first introduced the medical world to IgA nephropathy (IgAN). Fifty-five years later, its pathogenesis is still unclear, but treatments such as renin\u2013angiotensin\u2013aldosterone system inhibitors (RAAS-Is), tonsillectomies, and glucocorticoids are currently used worldwide. There have been great strides in the past 20 years since the discoveries of the specific dysregulation of mucosal immunity, galactose-deficient IgA1 (Gd-IgA1), and Gd-IgA1 immune complexes in patients with IgAN. According to these findings, a multi-hit hypothesis was developed, and this multi-hit hypothesis has provided several putative therapeutic targets. A number of novel agents, including molecularly targeted drugs for targets such as APRIL, plasma cells, complement systems, and endothelin, are undergoing clinical trials. Some candidate drugs have been found to be effective, with minimal side effects. Over half a century after the discovery of IgAN, these therapies will soon be available for clinical use.<\/jats:p>","DOI":"10.3390\/medicina60010054","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T09:56:27Z","timestamp":1703757387000},"page":"54","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["IgA Nephropathy: Beyond the Half-Century"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8185-2579","authenticated-orcid":false,"given":"Yoshio","family":"Shimizu","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Juntendo University Shizuoka Hospital, 1129 Nagaoka, Izunokuni 410-2295, Shizuoka, Japan"},{"name":"Shizuoka Research Center for Disaster Medicine, Juntendo University, Izunokuni 410-2295, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Tomino","sequence":"additional","affiliation":[{"name":"Asian Pacific Renal Research Promotion Office, Medical Corporation SHOWAKAI, 3-12-12 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, Juntendo University, 3-1-3 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2007.03.013","article-title":"A novel simpler histological classification for renal survival in IgA nephropathy: A retrospective study","volume":"49","author":"Manno","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semnephrol.2007.10.001","article-title":"Natural history of primary IgA nephropathy","volume":"28","author":"Berthoux","year":"2008","journal-title":"Semin. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Moriyama, T., Tanaka, K., Iwasaki, C., Oshima, Y., Ochi, A., Kataoka, H., Itabashi, M., Takei, T., Uchida, K., and Nitta, K. (2014). Prognosis in IgA nephropathy: 30-year analysis of 1012 patients at a single center in Japan. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091756"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1681\/ASN.2018111156","article-title":"Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1","volume":"30","author":"Rizk","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.molmed.2015.10.003","article-title":"Molecular Insights into the Pathogenesis of IgA Nephropathy","volume":"21","author":"KnoRobert","year":"2015","journal-title":"Trends Mol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Placzek, W.J., Yanagawa, H., Makita, Y., Renfrow, M.B., Julian, B.A., Rizk, D.V., Suzuki, Y., Novak, J., and Suzuki, H. (2018). Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. PLoS ONE., 13.","DOI":"10.1371\/journal.pone.0190967"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"HKVIN Study Group. Hong Kong study using valsartan in IgAN (HKVIN): A double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgAN with ACE inhibitors: A randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_9","first-page":"227","article-title":"Disease progression, response to ACEI\/ATRA therapy and influence of ACE gene in IgA nephritis","volume":"4","author":"Woo","year":"2007","journal-title":"Cell Mol. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/qjmed\/hci036","article-title":"Angiotensin-converting-enzyme inhibitors slow renal decline in IgAN, independent of tubulointerstitial fibrosis at presentation","volume":"98","author":"Kanno","year":"2005","journal-title":"QJM"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1046\/j.1523-1755.2000.00432.x","article-title":"ACEI\/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis","volume":"58","author":"Woo","year":"2000","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/08860220701260511","article-title":"Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy","volume":"29","author":"Horita","year":"2007","journal-title":"Ren. Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000013619","article-title":"Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgAN","volume":"20","author":"Nakamura","year":"2000","journal-title":"Am. J. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1291\/hypres.31.1711","article-title":"Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy","volume":"31","author":"Shimizu","year":"2008","journal-title":"Hypertens. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","article-title":"A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy","volume":"29","author":"Kawamura","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e194772","DOI":"10.1001\/jamanetworkopen.2019.4772","article-title":"Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy","volume":"2","author":"Hirano","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s11255-014-0818-7","article-title":"Effect of tonsillectomy and its timing on renal outcomes in Caucasian IgA nephropathy patients","volume":"46","author":"Vas","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000441852","article-title":"Tonsillectomy in a European Cohort of 1147 Patients with IgA Nephropathy","volume":"132","author":"Feehally","year":"2016","journal-title":"Nephron"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgAN: A randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA Nephropathy: A retrospective Analysis from the VALIGA Study","volume":"26","author":"Tesar","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"STOP-IgAN Investigators. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of Oral Methylprednisolone on Clinical Outcomes in Patients with IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of Oral Methylprednisolone oEdsn Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgAN (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Barratt","year":"2017","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ekir.2022.01.1073","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers","volume":"7","author":"Mathur","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"gfab117.004","DOI":"10.1093\/ndt\/gfab117.004","article-title":"FC 040 Interim results of phase 1 and 3 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of BION-1301 in patients with IgAN","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for Reduction of Proteinuria in IgA Nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14712598.2023.2213800","article-title":"Emerging role of monoclonal antibodies in the treatment of IgAN","volume":"23","author":"Maixnerova","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_33","unstructured":"(2023, December 05). A Study of Mezagitamab in Adults with Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy, Available online: https:\/\/www.clinicaltrials.gov\/ClinicalTrials.gov(NCT05174221)."},{"key":"ref_34","unstructured":"(2023, December 05). IONIS Pharma Press Releases: Ionis presents positive Phase 2 data in patients with IgAN at American Society of Nephrology\u2019s Kidney Week 2022. Available online: https:\/\/ir.ionispharma.com\/news-releases\/news-release-details\/ionis-presents-positive-phase-2-data-patients-IgAN."},{"key":"ref_35","first-page":"S164","article-title":"A phase 3, randomized, double-blind placebo-controlled study of atrasentan in patients with IgA nephropathy","volume":"6","author":"Heerspink","year":"2021","journal-title":"KI Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgAN: A prespecified interim analysis from a randomized, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Knoppova, B., Reily, C., King, R.G., Julian, B.A., Novak, J., and Green, T.J. (2021). Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment. Clin. Med., 10.","DOI":"10.3390\/jcm10194501"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00281-021-00883-8","article-title":"IgA glycosylation and immune complex formation in IgAN","volume":"43","author":"Suzuki","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00281-021-00871-y","article-title":"The mucosal immune system and IgA nephropathy","volume":"43","author":"Gesualdo","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_40","first-page":"8","article-title":"The renin-angiotensin system: Renal actions and blood pressure regulation","volume":"17","author":"Hall","year":"1991","journal-title":"Compr. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/ckj\/sfad082","article-title":"EMPA-KIDNEY: Expanding the range of kidney protection by SGLT2 inhibitors","volume":"16","author":"Sarafidis","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_43","unstructured":"Nuffield Department of Population Health Renal Studies Group (2022). SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet, 400, 1788\u20131801."},{"key":"ref_44","unstructured":"(2023, December 05). FDA Approves First Drug to Decrease Urine Protein in IgA Nephropathy, A Rare Kidney Disease|FDA, Available online: https:\/\/www.fda.gov."},{"key":"ref_45","first-page":"803","article-title":"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn\u2019s disease","volume":"43","author":"Andersson","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.tmrv.2019.09.004","article-title":"Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics","volume":"33","author":"Patriquin","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2169\/internalmedicine.9151-17","article-title":"Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria","volume":"57","author":"Kawakami","year":"2018","journal-title":"Int. Med."},{"key":"ref_49","first-page":"6093695","article-title":"A Case of Fulminant Meningococcemia: It Is All in the Complement","volume":"2017","author":"Hawkins","year":"2017","journal-title":"Case Rep. Infect. Dis."},{"key":"ref_50","first-page":"22","article-title":"The Most Expensive Drug in the World: To Continue or Discontinue, That Is the Question","volume":"33","author":"Khedraki","year":"2016","journal-title":"Fed. Pract."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-D\u00edaz, I., Martos, N., Llorens-Cebri\u00e0, C., \u00c1lvarez, F.J., Bedard, P.W., Vergara, A., Jacobs-Cach\u00e1, C., and Soler, M.J. (2023). Endothelin Receptor Antagonists in Kidney Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043427"},{"key":"ref_52","unstructured":"(2023, December 05). Available online: https:\/\/www.chinooktx.com\/file.cfm\/52\/docs\/asn-2022-atrasentan-affinity-igan-update-th-po497.pdf."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/54\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:43:01Z","timestamp":1760132581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["medicina60010054"],"URL":"https:\/\/doi.org\/10.3390\/medicina60010054","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}